Innate Pharma Investor Relations Material
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications. It generates its products from the expression platforms based on its phage display and dAb technologies. The company's lead product is NexoBrid, which is a treatment for severe burns that can be used outside of the European Union; and Phase 3 NExoBrid clinical trial is completed in Europe. Innate Pharma S.A. was founded in 2000 as Innate ImmunoPharmaceuticals S.A.; and it changed its name to Innate Pharma S.A. in 2011. Innate Pharma S.A. has operations in Saint Prex, Switzerland; and Sophia Antipolis, France. Innate Pharma S.A is based in Marseille, France.
Visa and Mastercard: The Global Payment Duopoly
Explore one of the world's largest and most discussed duopolies, from the origins of the credit card to its combined market value of $850 billion.
27 Feb 2024
The Rise of Google, Meta, Amazon, and Youtube in Advertising
Learn about the meteoric rise of digital advertising giants such as Google, Meta, Amazon, and YouTube, and their robust competitive advantages.
1 Mar 2024
Rubrik's 2024 IPO: What Investors Need To Know
Explore Rubrik's journey to a 2024 IPO, its innovative cybersecurity solutions, and strategic growth, highlighting its impact on the tech sector.
29 Feb 2024